66
Pharmacokinetics in the critically ill Department of Intensive Care Medicine Royal Brisbane Hospital University of Professor Jeffrey Lipman

Pharmacokinetics in the Critically Ill

Embed Size (px)

DESCRIPTION

Jeff Lipman explores how our conventional regimes for drug administration may be drastically underperforming when treating our critically ill patients

Citation preview

Page 1: Pharmacokinetics in the Critically Ill

Pharmacokinetics in the critically ill

Department of

Intensive Care MedicineRoyal Brisbane Hospital University of Queensland

Professor Jeffrey Lipman

Page 2: Pharmacokinetics in the Critically Ill
Page 3: Pharmacokinetics in the Critically Ill

Pharmacokinetics in the critically ill

Department of

Intensive Care MedicineRoyal Brisbane Hospital University of Queensland

Professor Jeffrey LipmanUnless you understand this

DRUGS DON’T WORK

Page 4: Pharmacokinetics in the Critically Ill

Intensive Care Med 2013; 39: 2070-2082

December 2013

Page 5: Pharmacokinetics in the Critically Ill

Important conceptRecommended dosages are obtained from

healthy volunteers and possibly (ward) “sick” patients

Page 6: Pharmacokinetics in the Critically Ill

Clinical pharmacology:drug development

Antibiotic regimens are derived from non-critically ill volunteers. Their haemodynamic system is normal, as is their liver and kidney blood flow. They have not leaky capillaries nor have they drips and pipes in every orifice.

Page 7: Pharmacokinetics in the Critically Ill
Page 8: Pharmacokinetics in the Critically Ill

SEPSIS

Increased Cardiac Output

Leaky Capillaries &/or altered protein binding

End Organ Dysfunction (e.g. renal or hepatic)

Increased CL Increased Vd Decreased CL

Low Plasma Concentrations

High Plasma Concentrations

Normal Organ Function

Normal Plasma Concentrations

Unchanged Vd

Roberts and Lipman Critical Care Medicine 2009; 37:840-851

Page 9: Pharmacokinetics in the Critically Ill

LOW EXPOSURE TO ANTIBIOTICS ENABLES

DEVELOPMENT OF RESISTANCE

Critical Care Medicine August 2008;36:2433-40

Page 10: Pharmacokinetics in the Critically Ill

Cmax Peak ConcentrationCmin Trough Concentrationt1/2 Half-life

V (or VD) Volume of distribution

AUC Area under curveCl Clearance

Protein binding

Antibiotic related IMPORTANTIMPORTANTpharmacokinetic parameters

Page 11: Pharmacokinetics in the Critically Ill

Volume of Distribution

Page 12: Pharmacokinetics in the Critically Ill

Gous et al Anaesth Intens Care 1995

Page 13: Pharmacokinetics in the Critically Ill

Gous et al Anaesth Intens Care 1995

Page 14: Pharmacokinetics in the Critically Ill

AMIKACIN DATA Marik P. Anaesth Intens Care 1993

Page 15: Pharmacokinetics in the Critically Ill

….we have found that higher-than-recommended loading and daily doses of vancomycin seem to be necessary to rapidly achieve therapeutic serum concentrations.

35mg/kg loading 35mg/kg/day

Page 16: Pharmacokinetics in the Critically Ill

Col

istin

CM

SSTANDARD DOSE INSUFFICIENT

Plachouras et al Antimicrob Agents Chemother 2009;53:3420-6

Page 17: Pharmacokinetics in the Critically Ill

Antibiotics that stay in extravascular and extracellular space ie that don’t penetrate “solid” organs, (hydrophilic tendencies) namely AMINOGLYCOSIDES

GLYCOPEPTIDES

β-LACTAMS (to a lesser extent)

COLISTIN

VOLUME OF DISTRIBUTIONALTERATIONS IN ICU

Page 18: Pharmacokinetics in the Critically Ill

DOSE ADJUSTMENT – MESSAGE 1

LOADING DOSE

INCREASED VOLUME OF DISTRIBUTION MEANS LOADING DOSE

TO “FILL UP ALL SPACES”

Page 19: Pharmacokinetics in the Critically Ill

Critical Care Medicine March 2009Revised from Clinical Pharmacokinetics 2006

Page 20: Pharmacokinetics in the Critically Ill

Increased CL

Critical Care Medicine March 2009Revised from Clinical Pharmacokinetics 2006

Page 21: Pharmacokinetics in the Critically Ill

Increased CL

Critical Care Medicine March 2009Revised from Clinical Pharmacokinetics 2006

Page 22: Pharmacokinetics in the Critically Ill

1

100

0 4 8 12

Time (hr)

Co

nc

en

tra

tio

n (

mg

/L) (A)

1

100

0 4 8 12

Time (hr)

Co

nc

en

tra

tio

n (

mg

/L)

(B)

1st dose Day 3-6

1. Cefpirome levels lower2. No difference between D1 vs later dose

CEFEPIME (O) vs CEFPIROME ()�

Page 23: Pharmacokinetics in the Critically Ill

0

50

100

150

200

250

0 50 100 150 200 250 300Creatinine Clearance (mL/min)

Dru

g C

lea

ran

ce (m

L/m

in)

Cefepime CefpiromeLipman et al Anesth Analg 2003

Creatinine clearance

Page 24: Pharmacokinetics in the Critically Ill

0

50

100

150

200

250

0 50 100 150 200 250 300Creatinine Clearance (mL/min)

Dru

g C

lea

ran

ce (m

L/m

in)

Cefepime Cefpirome

Creatinine clearance

Augmented Renal ClearanceCr Cl>130ml/min

Lipman et al Anesth Analg 2003

Page 25: Pharmacokinetics in the Critically Ill
Page 26: Pharmacokinetics in the Critically Ill

AUGMENTED RENAL CLEARANCE – who gets it?

Page 27: Pharmacokinetics in the Critically Ill

Those manifesting ARC were younger (P <0.001), male (P = 0.012), with lower acute physiology and chronic health evaluation (APACHE) II (P= 0.008) and modified sequential organ failure assessment (SOFA) scores (P = 0.013), and higher cardiac indices (P = 0.013). In multivariate analysis, age ≤50 years, trauma, and a modified SOFA score ≤4, were identified as significant risk factors.

AUGMENTED RENAL CLEARANCE – who gets it?

Page 28: Pharmacokinetics in the Critically Ill

UDY et al Critical Care Medicine March 2014: 42 : 520-527

Page 29: Pharmacokinetics in the Critically Ill

Measurements and Main Results: …. Overall, 65.1% manifested augmented renal clearance on at least one occasion during the first seven study days; themajority (74%) of whom did so on more than or equal to 50% of their creatinine clearance measures.

65.1%

UDY et al Critical Care Medicine March 2014: 42 : 520-527

Page 30: Pharmacokinetics in the Critically Ill

AUGMENTED RENAL CLEARANCE – how long does it last?

UDY et al Critical Care Medicine March 2014: 42 : 520-527

Page 31: Pharmacokinetics in the Critically Ill

Conclusions: Augmented renal clearance appears to be a common finding in this patient group, with sustained elevation of creatinine clearance throughout the first week in ICU.

UDY et al Critical Care Medicine March 2014: 42 : 520-527

Page 32: Pharmacokinetics in the Critically Ill

IN SUMMARY

Younger patients who have an inflammatory response (any) with “normal” renal function

Particularly those that need fluid loading and or inotropic support to defend a blood pressure

AUGMENTED RENAL CLEARANCE – who gets it?

Page 33: Pharmacokinetics in the Critically Ill

AUGMENTED RENAL CLEARANCE

CHEST 2012; 142(1):30–39

Page 34: Pharmacokinetics in the Critically Ill

Trough conc/MIC ratio vs Creat Cl

Udy et al Chest 2012;142:30-39

Page 35: Pharmacokinetics in the Critically Ill

ARC pictorial explanation

Udy et al Clin Pharmacokinet 2010; 49:1-16

Page 36: Pharmacokinetics in the Critically Ill

IF YOU DON’T LOOK PROPERLYYOU WON’T SEE IT.

Page 37: Pharmacokinetics in the Critically Ill

DOSE ADJUSTMENT – MESSAGE 2

INCREASE FREQUENCY

INCREASED CLEARANCES MEANS LOW TROUGHS

FOR AB’s THAT NEED t>MIC NEED TO INCREASE FREQUENCY

Page 38: Pharmacokinetics in the Critically Ill

Critically ill patients have lowered protein concentrations and thus altered protein binding, unpredictable volumes of distribution, and vastly altered clearances compared to non-critically ill patients.

Protein binding

Page 39: Pharmacokinetics in the Critically Ill

More than 40% of all patients had a baseline serum albumin concentration of 25 g/l or less

AT BASELINE

2006;333:1044

Page 40: Pharmacokinetics in the Critically Ill

1

10

100

1000

0 200 400 600 800 1000 1200 1400 1600

Time (min)

Pla

sma

ceftr

iaxo

ne c

once

ntra

tion

(mg/

L)

Joynt et al J Antimicrob Chemother 2001

TOTAL UNBOUND/FREE

CEFTRIAXONE

Page 41: Pharmacokinetics in the Critically Ill

ERTAPENEM 1GM/DAY (?..!)

Level ‘therapeutic’ target = 100% f T>MIC

DOSE INCR 1GM BD

DOSE INCR 1GM TDS

DOSE INCR 1GM TDSAS EXTENDED INFUSION

DOSE INCR 1GM TDSAS EXTENDED INFUSION

and only then did we get adequate levels!

Page 42: Pharmacokinetics in the Critically Ill

More than 40% of all patients had a baseline serum albumin concentration of 25 g/l or less

AT BASELINE

2006;333:1044

Page 43: Pharmacokinetics in the Critically Ill

DOSE ADJUSTMENT – MESSAGE 3

INCREASE FREQUENCY

BEWARE HIGHLY PROTEIN BOUNDANTIBIOTICS

USUALLY MEANS QUICKER ELLIMINATION (in ICU)

Page 44: Pharmacokinetics in the Critically Ill

Reviewed in Clinical Pharmacokinetics January 2011

Reviewed in Clinical Pharmacokinetics January 2013

Page 45: Pharmacokinetics in the Critically Ill

Sepsis changes PK

Extracorporeal circuits

Altered CL and Increased Vd cf AKI

? Plasma concentrations

Page 46: Pharmacokinetics in the Critically Ill

Kidney Filter

Ultrafiltrate Dialysate

FLOW

FLOW

Semi-permeable Membrane

(C)RRT(Continuous) Renal

Replacement Therapy

Page 47: Pharmacokinetics in the Critically Ill

Ultrafiltrate

FLOW

Semi-permeable Membrane

CRRT Effects on Electrolytes and Water ..…

and Drugs.

+/- Dialysate

UrCr

K Ca PO4

UrCrCr

CrCr

UrUr

K Ca PO4

H2OH2O

FLOW

Page 48: Pharmacokinetics in the Critically Ill

BEST WE HAVE

Choi et al Crit Care Med 2009;37:2268-82

Page 49: Pharmacokinetics in the Critically Ill

DOSE ADJUSTMENT – MESSAGE 4

COME DO A PhD WITH US

EXTRACORPOREAL CIRCUITS

??

Page 50: Pharmacokinetics in the Critically Ill

Sepsis changes PK

Extracorporeal circuits

Altered CL and Increased Vd cf AKI

? Plasma concentrations

If dosing does not account for these changes – sub-optimal therapy!

Sub-optimal patient outcomes

Page 51: Pharmacokinetics in the Critically Ill

TDM DEFINITION

Therapeutic Drug Monitoring (TDM)

refers to analysis and subsequent interpretation of drug concentrations in biological fluids

Page 52: Pharmacokinetics in the Critically Ill

PLACE

TDM should be used to

maximise efficacy

minimize toxicity

To personalise dosing for high probability of therapeutic success, prevent development of resistance, provide low probability of toxicity

Page 53: Pharmacokinetics in the Critically Ill

AMINOGLYCOSIDES AND GLYCOPEPTIDES

Assays developed for side-effect profiles

Large market to prevent toxicity

Rapid turnaround, easy to use immunoassays

TDM should be used to

maximise efficacy

minimize toxicity

Page 54: Pharmacokinetics in the Critically Ill

BETA-LACTAMS

Safe drugs

Large therapeutic range

TDM should be used to

maximise efficacyminimize toxicity

Page 55: Pharmacokinetics in the Critically Ill

J Chromatogr B 2010;878:2039-2043

Page 56: Pharmacokinetics in the Critically Ill

Roberts JA et al. Int J Antimicrob Agents 2010;36:332-39

Roberts JA, Hope WW, Lipman J. Int J Antimicrob Agents 2010;35:419-20

Page 57: Pharmacokinetics in the Critically Ill

Roberts JA et al. Int J Antimicrob Agents 2010;36:332-39

A total of 236 patients were subject to TDM over an 11-month period. The mean ± standard deviation age was 53.5 ± 18.3 years. Dose adjustment was required in 175 (74.2%) of the patients, with 119 of these patients (50.4%) requiring dose increases after the first TDM.

Dose adjustment was required in 175 (74.2%)

Page 58: Pharmacokinetics in the Critically Ill

For various reasons therapeutic drug monitoring (TDM) of most antibiotics is difficult but not impossible. We have set up a TDM service for all our beta-lactam use and have (not surprisingly ) shown that in more than half of our ICU patients we are dose adjusting once receiving back a drug level!

MESSAGE 5

Page 59: Pharmacokinetics in the Critically Ill

MAIN DIFFERENCES IN ICU

Increased volume of distribution

Increased cardiac output

Increased hepatic and renal blood flows

Low serum proteins, hence protein binding

Increased clearances

Renal replacement techniques unique to ICUs

Page 60: Pharmacokinetics in the Critically Ill

Sepsis changes PK

Extracorporeal circuits

Altered CL and Increased Vd cf AKI

? Plasma concentrations

If dosing does not account for these changes – sub-optimal therapy!

Sub-optimal patient outcomes

Page 61: Pharmacokinetics in the Critically Ill

DOSE ADJUSTMENT – MESSAGE 1

LOADING DOSE

INCREASED VOLUME OF DISTRIBUTION MEANS LOADING DOSE

TO “FILL UP ALL SPACES”

Page 62: Pharmacokinetics in the Critically Ill

DOSE ADJUSTMENT – MESSAGE 2

INCREASE FREQUENCY

INCREASED CLEARANCES MEANS LOW TROUGHS

FOR AB’s THAT NEED t>MIC NEED TO INCREASE FREQUENCY

Page 63: Pharmacokinetics in the Critically Ill

DOSE ADJUSTMENT – MESSAGE 3

INCREASE FREQUENCY

BEWARE HIGHLY PROTEIN BOUNDANTIBIOTICS

USUALLY MEANS QUICKER ELLIMINATION (in ICU)

Page 64: Pharmacokinetics in the Critically Ill

DOSE ADJUSTMENT – MESSAGE 4

EXTRACORPOREAL CIRCUITS

??

Page 65: Pharmacokinetics in the Critically Ill

For various reasons therapeutic drug monitoring (TDM) of most antibiotics is difficult but not impossible. We have set up a TDM service for all our beta-lactam use and have (not surprisingly ) shown that in more than half of our ICU patients we are dose adjusting once receiving back a drug level!

MESSAGE 5

Page 66: Pharmacokinetics in the Critically Ill

THE END !

[email protected]

www.som.uq.edu.au/btccrc